Contact
The newspaper ARA devotes an article to the recent findings of the Combinatorial Chemistry laboratory at IRB Barcelona, headed by Fernando Albericio, in collaboration with the pharmaceutical company BioMar.
Published in Angewandte Chemie, the researchers describe the laboratory synthesis of baringolin, a product isolated from a marine microorganism that, in small doses, inhibits the growth of antibiotic-resistant bacteria.
ARA also highlights the origin of the name of the molecule and the double importance of the finding. Reproducing these products in the laboratory protects the species that contains these substances of pharmaceutical interest and, at the same time, enables their large scale production.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
